Related Experiment Video
Updated: May 15, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Case Report of Dermatomyositis With Features of the Wong Variant Developing Post-Trastuzumab Therapy for Breast
Lauren C LaMonica1, Margaret E Lang Houser2, Paul W Harms2,3
1University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract:
Drug-induced dermatomyositis can be challenging to distinguish from paraneoplastic dermatomyositis. Rarely, antibodies directed against human epidermal growth factor receptor 2 (HER-2), such as trastuzumab, may trigger dermatomyositis, and immune checkpoint inhibitors may incite the Wong variant of dermatomyositis, characterised by clinical and histopathologic features of pityriasis rubra pilaris, including monomorphic keratotic papules. We present an unusual case of dermatomyositis with features of the Wong variant occurring in a 51-year-old female with a history of breast cancer after completion of adjuvant therapy with trastuzumab.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
